Background and Objectives It was reported that low molecular weight heparin LMWH was more effective than unfractionated heparin in patients with acute coronary syndrome. Recent studies have shown that the pathophysiology of restenosis in stented lesions was different from those of nonstented lesions. Treatment strategies designed to limit cellular proliferation that were ineffective in nonstented lesions may be efficacious in reducing in-stent restenosis. This study was aimed to compare the clinical and angiographic results of LMWH nadroparin after coronary stenting with those of conventional ticlopidine regimen. Materials and Methods Patients were eligible for inclusion if they had angina and or objective evidence of myocardial ischemia, and a significant 50% stenosis that was documented on a recent coronary angiogram. After stenting, prospective randomized comparison study was performed. Patients were randomly assigned to either nadroparin 200 IU kg, sc, bid or ticlopidine 250 mg bid plus aspirin 200 mg qd treatment groups. Repeat coronary angiography was performed at 236 90 days after stenting, and quantitative coronary angiographic analysis QCA was done. Results Intracoronary stent implantation was performed in eighty five lesions in eighty one patients ticlopidine 40, nadroparin 41 . There was no significant difference in any baseline clinical angiographic variables between the two treatment groups. There were no subacute stent thrombosis, infarction and death in both groups. Six-month event-free survival was 36 90% in the ticlopidine group and 35 85.4% in the nadroparin group. Follow-up quantitative angiographic data such as late loss 1.35 0.70 vs 1.32 0.69 , loss index 0.53 0.70 vs 0.56 0.23 and restenosis rate 36% vs 25.8% were not different between ticlopidine and nadroparin groups. Conclusion Effects of nadroparin were not different from those with ticlopidine therapy in the prevention of restenosis and subacute stent thorombosis after coronary stenting. Clinical outcomes between two strategies were similar. Low molecular weight heparin may be an alternative to ticlopidine in patients that ticlopidine cannot be administered because of severe adverse effects. Korean Circulation J 1999 ; 29 3 : 259-265

